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No Need for the Needle (at First)
I
nthisissueofDiabetesCare,Chenetal.
(1) describe an approach to the initial
treatment of newly diagnosed type 2
diabetic patients with severe hyperglyce-
mia (fasting plasma glucose [FPG] con-
centrations 300 mg/dl or random
plasmaglucoseconcentrations400mg/
dl) entailing intensive insulin therapy
during 10 to 14 days of hospitalization.
Following this, half of the patients were
randomized to continued insulin treat-
ment and the other half to oral antidiabe-
tes drugs (OAD), starting with metformin
in overweight and obese patients and a
sulfonylurea (SU), gliclazide, in lean pa-
tients. If satisfactory control was not ob-
tained with a single OAD, a combination
of metformin and the SU was used. Doses
of insulin and the OAD were adjusted at
eachoutpatientvisitevery2weeksduring
the ﬁrst 2 months and every 4 weeks for
another 4 months. Oral glucose tolerance
tests were performed after the intensive
insulin therapy: once just before random-
ization and again 6 months later. At that
time, patients in the insulin group were
switched to OAD and all patients were
followed for another 6 months.
As expected, FPG concentrations
were no different at randomization: how-
ever, they were signiﬁcantly increased in
the OAD group compared with those
maintained on insulin. A1C levels were
signiﬁcantly lower at 3 and 6 months in
patients maintained on insulin compared
with those given OAD. They also re-
mained signiﬁcantly lower 6 months after
the insulin patients were switched to
OAD.
Glucoseandinsulinresponsesamong
the insulin and OAD groups to the oral
glucose tolerance tests were compared at
randomization and 6 months later. To
their credit, the authors compared only
those patients who had achieved an A1C
level 7.0% (22 of 24 in the insulin
group and 8 of 18 in the OAD group). As
expected, glucose responses were signiﬁ-
cantly improved in both groups com-
pared with those at randomization,
although there were no differences be-
tween groups. Conversely, insulin re-
sponses (assessed by homeostasis model
assessment of -cell function, insulino-
genic index, and insulin area under the
curve) were all signiﬁcantly higher not
only in both groups at 6 months com-
pared with randomization but also in the
insulin group compared with the OAD
group at 6 months.
So, should there be a rush to insulin
as the initial therapy in newly diagnosed
type 2 diabetic patients? I think not. Just
as one should not rush to judgment, one
should carefully examine clinical evi-
dence when deciding on treatments for
type 2 diabetes. First of all, hospitaliza-
tion for implementing insulin treatment
of newly diagnosed patients is not recom-
mended (2) and is simply impractical, at
least in the U.S. and Europe. Achieving
excellent control after starting insulin
therapy in ofﬁce or outpatient settings
will take much longer than 2 weeks
(probably more like 2 months). Further-
more, even after quickly achieving excel-
lent control and maintaining it for 6
months, most of these patients still re-
quired OAD. The authors postulate that
perhaps a 2-week course of intensive in-
sulin therapy in patients with less severe
hyperglycemia (in contrast to the severely
hyperglycemic patients in their study)
mightinducelong-termglycemiccontrol.
Giventhemuchgreatereffortsonthepart
of both patients and physicians to initiate
treatment with insulin (see below), we
need evidence, not hypotheses, to recom-
mend this course.
The question arises (and the authors
discuss)whethertheimprovedinsulinse-
cretion in the insulin group is due to de-
creased glucose toxicity or to insulin per
se.Althoughtheyciteaninvitropaper(3)
tosupportthelatterpossibility,PeterBut-
ler discussed the issue of insulin affecting
apoptosis of the -cell at a symposium
during the recent ADA Scientiﬁc Sessions
and stated that there was no human evi-
dence that this was so. Furthermore, the
presence of signiﬁcantly higher FPG con-
centrationsafterstartingpatientsonOAD
supports suppression of glucotoxicity as
an explanation. OAD dosing is an impor-
tant issue in this paper, as patients not
achieving an A1C level 7.0% were tak-
ing only half the maximal dose of the SU
(see the supplementary Table in the on-
line appendix of ref. 1, available at http:/
dx.doi.org/10.2337/dc08-0075).Because
doses of the OAD at 12 months were not
provided, it is not possible to ascertain
whetherthesigniﬁcantA1Cdifferencesat
that time might also be related to the con-
tinuation of submaximal doses of the SU
in patients who had not achieved an A1C
level of 7.0%.
Even allowing for the possibility that
initial intense insulin therapy might have
a direct effect (independent of glucose
toxicity) on -cell function because only
patients with A1C levels 7.0% were
compared, how clinically important is
this? Given that there is virtually no clin-
icaldevelopmentorprogressionofmicro-
vascular complications at A1C levels
7.0% (4–8), this, not surrogate mea-
sures of insulin secretion, should be our
primary goal. Indeed, this goal can be
achieved in almost all severely hypergly-
cemic,newlydiagnosedtype2patientsby
initial treatment with high doses of SU (9).
(Note that A1C levels in this study were
measured by a boronate afﬁnity rather than
anelectrophorosismethod,withtheformer
yielding values 1% higher.)
Moreover, patients have diabetes for
many, many years. How important and
howpracticalisinitialinsulintherapythat
might preserve some -cell function dur-
ing the ﬁrst year or so after the diagnosis?
As in the study by Chen et al. (1), initial
insulin therapy in all studies supporting
this approach was administered by either
insulin pumps (9–12) or multiple daily
injections (12,13)—modalities of treat-
ment not easily accomplished, especially
quickly,intheofﬁceoroutpatientsetting.
Furthermore, whatever the amount of
-cellfunctionpreserved,itisnotenough
to preclude the need for OAD when insu-
lin is discontinued in a substantial pro-
portionofthesepatients(9–13).Tojudge
the utility of initial insulin therapy, con-
sider what is required from both patients
and providers when either insulin or
OADisstarted(Table1).Giventhecostto
patients and their physicians and the very
limited and unproven clinical beneﬁt of
some possible brief preservation of -cell
functionthatmightleadtoimprovedcon-
trol for a short initial period during the
manyyearsofdiabetes,itseemstomethat
there is little clinical evidence that insulin
should be the initial treatment for type 2
diabetes.
Inmyview,OADshouldbetheinitial
treatment for type 2 diabetes as long as
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This is much easier for both patients and
providers. OAD should be increased as
necessarytomaintainthiswell-supported
A1C goal. However, as soon as OADs are
unable to maintain this target, insulin
should be initiated. This is not being
done. For instance, the A1C level of
nearly 1,000 patients on combination
OAD in a large HMO was, on average,
9.2% when insulin was started (14).
While on combination OAD, these pa-
tients spent 30 months with A1C levels
8.0% and 58 months with A1C levels
7.0% before starting insulin therapy.
Therefore, our biggest challenge is to
overcome the insulin resistance of pa-
tients and, probably more importantly,
of providers. Unfortunately, clinical in-
ertia is alive and well and, in my opin-
ion, is the main reason why so many
type 2 diabetic patients’ diabetes re-
mains uncontrolled.
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Table 1—Provider and patient responsibilities at the initiation of treatment
Provider Patient
Insulin
Teach the following: Learn what is taught.
Different insulin preparations Inject suggested insulin doses.
Time course of actions Perform SMBG at appropriate times.
How to draw up insulin Maintain frequent contact with
provider. How and where to inject
Recognition of hypoglycemia
Treatment of hypoglycemia
SMBG (and all that entails)
Maintain frequent interactions with patient after
initiating insulin therapy to establish
appropriate dose.
Maintain close follow-up to reduce dose after
decreased glucose toxicity restores baseline
insulin secretion.
OAD
Teach recognition and treatment of
hypoglycemia (not necessary for metformin).
Swallow suggested doses at
appropriate times.
Measure FPG concentrations initially every 2–3
weeks to adjust doses as necessary.
Have FPG concentrations measured
at suggested times.
Maintain patient contact.
SMBG, self-monitoring of blood glucose.
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